AU2014205557B2 - Treatment of vasculopathy with prostacyclin and mesenchymal stem cells - Google Patents

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Download PDF

Info

Publication number
AU2014205557B2
AU2014205557B2 AU2014205557A AU2014205557A AU2014205557B2 AU 2014205557 B2 AU2014205557 B2 AU 2014205557B2 AU 2014205557 A AU2014205557 A AU 2014205557A AU 2014205557 A AU2014205557 A AU 2014205557A AU 2014205557 B2 AU2014205557 B2 AU 2014205557B2
Authority
AU
Australia
Prior art keywords
cells
mesenchymal stem
stem cell
treprostinil
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014205557A
Other languages
English (en)
Other versions
AU2014205557A1 (en
Inventor
Roger M. Ilagan
Roger Jeffs
Thomas Petersen
Michael Wade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of AU2014205557A1 publication Critical patent/AU2014205557A1/en
Application granted granted Critical
Publication of AU2014205557B2 publication Critical patent/AU2014205557B2/en
Priority to AU2017258866A priority Critical patent/AU2017258866B2/en
Priority to AU2019200504A priority patent/AU2019200504B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014205557A 2013-01-09 2014-01-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Active AU2014205557B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017258866A AU2017258866B2 (en) 2013-01-09 2017-11-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2019200504A AU2019200504B2 (en) 2013-01-09 2019-01-25 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750458P 2013-01-09 2013-01-09
US61/750,458 2013-01-09
PCT/US2014/010623 WO2014110094A1 (en) 2013-01-09 2014-01-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017258866A Division AU2017258866B2 (en) 2013-01-09 2017-11-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Publications (2)

Publication Number Publication Date
AU2014205557A1 AU2014205557A1 (en) 2015-07-23
AU2014205557B2 true AU2014205557B2 (en) 2017-08-10

Family

ID=51061108

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014205557A Active AU2014205557B2 (en) 2013-01-09 2014-01-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2017258866A Active AU2017258866B2 (en) 2013-01-09 2017-11-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2019200504A Active AU2019200504B2 (en) 2013-01-09 2019-01-25 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017258866A Active AU2017258866B2 (en) 2013-01-09 2017-11-08 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2019200504A Active AU2019200504B2 (en) 2013-01-09 2019-01-25 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Country Status (10)

Country Link
US (4) US10080730B2 (https=)
EP (3) EP2943069B1 (https=)
JP (2) JP6431850B2 (https=)
KR (2) KR102466885B1 (https=)
CN (1) CN105025720B (https=)
AU (3) AU2014205557B2 (https=)
CA (1) CA2897805C (https=)
ES (3) ES2963968T3 (https=)
IL (2) IL239603A (https=)
WO (1) WO2014110094A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713988T3 (es) * 2012-08-01 2019-05-24 United Therapeutics Corp Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
EP2879682B1 (en) 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
EP2943069B1 (en) 2013-01-09 2018-08-15 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3328413B1 (en) * 2015-07-29 2024-09-04 Indiana University Research and Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
EP3534917B1 (en) * 2016-10-24 2022-08-24 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
JP2020502078A (ja) * 2016-11-30 2020-01-23 パイアン・バイオテクノロジー・インコーポレイテッドＰａｅａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎｃ． ミトコンドリアを含む医薬組成物
CN107602690B (zh) * 2017-11-03 2020-10-20 中国医学科学院阜外医院 肺动脉高压相关的ptgis基因突变及其应用
US12233092B2 (en) 2018-04-10 2025-02-25 Brainstorm Cell Therapeutics Ltd. MSC-NTF specific exosomes and use thereof
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
MX2021003866A (es) 2018-10-05 2021-09-08 Xenotherapeutics Inc Productos y metodos de xenotransplante.
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
JP2022526820A (ja) * 2019-04-08 2022-05-26 シンバイオセルテック・エルエルシー 間葉系幹細胞およびそのエクソソームによる微小血管障害の治療
US10881693B2 (en) * 2019-04-09 2021-01-05 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4004191A4 (en) 2019-07-26 2022-10-12 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same
WO2021020666A1 (en) * 2019-07-26 2021-02-04 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same
WO2021207282A2 (en) 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
US20250082781A1 (en) * 2021-12-29 2025-03-13 Salk Institute For Biological Studies Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d3
EP4285915A1 (en) * 2022-06-03 2023-12-06 Medizinische Hochschule Hannover Human mesenchymal stem cell-conditioned medium for use in treatment of chronic heart-lung and vascular diseases, in particular, of pulmonary arterial hypertension (pah)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
WO2004084921A1 (en) * 2003-03-28 2004-10-07 Angioblast Systems Incorporated Perivascular mesenchymal precursor cell induced blood vessel formation
US20080050349A1 (en) * 1999-03-26 2008-02-28 Stewart Duncan J Cell based therapy for the pulmonary system
US20090274665A1 (en) * 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
WO2012027740A1 (en) * 2010-08-27 2012-03-01 University Of Miami Bone marrow derived cd271 precursor cells for cardiac repair

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5071741A (en) 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
AU672775B2 (en) 1992-01-21 1996-10-17 Cobe Laboratories Inc. Method of freezing cells and cell-like materials
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
EP0748215B1 (en) 1994-02-17 2003-05-28 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
WO1997021824A2 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
AU4659697A (en) 1996-10-03 1998-04-24 Regents Of The University Of California, The Cryopreservation of human adult and fetal pancreatic cells and human platelets
KR100695590B1 (ko) 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US9320829B2 (en) 2000-03-15 2016-04-26 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001097872A1 (en) 2000-06-22 2001-12-27 Austin Sam L Bioadhesive compositions and methods of preparation and use
WO2004050180A2 (en) 2002-11-30 2004-06-17 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
DE602004028155D1 (de) 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
CA3022238A1 (en) * 2005-08-19 2007-02-22 Duke University Stem cell derived factors for treating pathologic conditions
US20070065414A1 (en) 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
WO2008077094A2 (en) 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
EP3763376A1 (en) * 2007-02-12 2021-01-13 Celularity, Inc. Treatment of inflammatory diseases using placental stem cells
JP2011015609A (ja) * 2007-10-30 2011-01-27 Asahikawa Medical College 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法
EP2254586B1 (en) * 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
ES2713988T3 (es) 2012-08-01 2019-05-24 United Therapeutics Corp Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
EP2879682B1 (en) * 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP2943069B1 (en) 2013-01-09 2018-08-15 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9924630B2 (en) 2014-11-14 2018-03-27 Luitauras Kairys Device for connecting two rakes
EP3534917B1 (en) 2016-10-24 2022-08-24 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US20080050349A1 (en) * 1999-03-26 2008-02-28 Stewart Duncan J Cell based therapy for the pulmonary system
WO2004084921A1 (en) * 2003-03-28 2004-10-07 Angioblast Systems Incorporated Perivascular mesenchymal precursor cell induced blood vessel formation
US20090274665A1 (en) * 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
WO2012027740A1 (en) * 2010-08-27 2012-03-01 University Of Miami Bone marrow derived cd271 precursor cells for cardiac repair

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ISHll, M. et al.: "Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia", ATHEROSCLEROSIS, (2009) vol. 206, pages 109-118 *
LAU, A.N et al.: "Stem Cells and Regenerative Medicine in Lung Biology and Diseases", MOLECULAR THERAPY, (2012) vol. 20, no. 6, pages 1116-1130 *
RUAN CHENG-HUAI et al.: "Prostacyclin therapy for pulmonary arterial hypertension.", TEXAS HEART INSTITUTE JOURNAL (2010) Vol. 37, No. 4, Pages 391 - 399 *
UMAR, S. et al.: "Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, (2010) vol. 8, pages 1-11 *

Also Published As

Publication number Publication date
EP2943069B1 (en) 2018-08-15
IL255547B (en) 2018-11-29
EP3878452A1 (en) 2021-09-15
JP6709834B2 (ja) 2020-06-17
CN105025720B (zh) 2019-06-14
US12274684B2 (en) 2025-04-15
KR102348611B1 (ko) 2022-01-06
AU2014205557A1 (en) 2015-07-23
JP2019031566A (ja) 2019-02-28
US11141393B2 (en) 2021-10-12
WO2014110094A1 (en) 2014-07-17
EP3415150B1 (en) 2021-08-18
KR20150103211A (ko) 2015-09-09
KR20220003673A (ko) 2022-01-10
EP2943069A4 (en) 2016-07-27
ES2697573T3 (es) 2019-01-25
CN105025720A (zh) 2015-11-04
AU2019200504A1 (en) 2019-02-14
AU2017258866A1 (en) 2017-11-30
KR102466885B1 (ko) 2022-11-11
EP3415150A1 (en) 2018-12-19
US20240100003A1 (en) 2024-03-28
AU2017258866B2 (en) 2018-10-25
EP2943069A1 (en) 2015-11-18
ES2888909T3 (es) 2022-01-10
US11839596B2 (en) 2023-12-12
IL255547A (en) 2018-01-31
IL239603A0 (en) 2015-08-31
US20190160032A1 (en) 2019-05-30
US20140193379A1 (en) 2014-07-10
JP2016505623A (ja) 2016-02-25
EP3878452B1 (en) 2023-09-20
US10080730B2 (en) 2018-09-25
US20220062210A1 (en) 2022-03-03
AU2019200504B2 (en) 2020-12-03
CA2897805C (en) 2023-03-21
ES2963968T3 (es) 2024-04-03
CA2897805A1 (en) 2014-07-17
JP6431850B2 (ja) 2018-11-28
IL239603A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
US12274684B2 (en) Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US11666602B2 (en) Treatment of pulmonary arterial hypertension with mesenchymal stem cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)